TheEdgeResearch
Home / Stocks / CPRX

Catalyst Pharmaceuticals, Inc. (CPRX)

NASDAQ Healthcare Biotechnology
$31.45 ▲ +0.03%
Market Cap
$3.85B
Sector
Healthcare
Industry
Biotechnology
Beta
0.74
52-Wk Range
19.05-32.56
CEO
Richard John Daly
Country
US
Currency
USD

Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients d…

Open full interactive analysis & DCF →